Related Experiment Videos
Lack of haematological effect of oral vanadium treatment in rats
1Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Abstract:
Haematological effects of oral administration of ammonium metavanadate 0.19 mmol V/kg/day, vanadyl sulphate 0.15 mmol V/kg/day, and bis(maltolato)oxovanadium (i.v.) 0.18 mmol V/kg/day in drinking water for 12 weeks were investigated in Wistar rats. Some selected haematological indices of the peripheral blood, including haematocrit, haemoglobin, erythrocyte count, reticulocyte percentage, leukocyte count and its differential count, platelet count, and osmotic fragility of the erythrocyte were determined using the standard methods. It was found that, throughout the 12-week experimental period, there were no significant differences between the untreated controls and various groups of vanadium-treated rats in all of the parameters measured. It is thus concluded that ammonium metavanadate, vanadyl sulphate, and bis(maltolato) oxovanadium (i.v.), at least at the doses and at the duration of treatment employed, do not produce significant haematological toxicity in rats.
Insights
This study found that common vanadium compounds, including ammonium metavanadate and vanadyl sulfate, did not cause significant haematological toxicity in rats over 12 weeks. These vanadium treatments showed no adverse effects on blood cell counts or parameters.
Area of Science:
- Environmental toxicology
- Hematology
- Inorganic chemistry
Background:
- Vanadium compounds are used in various industrial applications.
- Understanding the potential health effects, particularly haematological impacts, is crucial for risk assessment.
- Previous research on vanadium toxicity has yielded mixed results, necessitating further investigation.
Purpose of the Study:
- To investigate the haematological effects of oral administration of ammonium metavanadate, vanadyl sulphate, and bis(maltolato)oxovanadium (i.v.) in Wistar rats.
- To determine if these vanadium compounds induce significant toxicity in key haematological parameters.
- To assess the safety profile of these vanadium compounds at specific doses and durations.
Main Methods:
- Wistar rats were administered ammonium metavanadate, vanadyl sulphate, or bis(maltolato)oxovanadium (i.v.) in drinking water for 12 weeks.
- Standard haematological methods were used to measure parameters including haematocrit, haemoglobin, erythrocyte count, leukocyte count, and platelet count.
- Osmotic fragility of erythrocytes was also assessed to evaluate red blood cell stability.
Main Results:
- No significant differences were observed in haematocrit, haemoglobin, or erythrocyte counts between vanadium-treated groups and controls.
- Leukocyte counts, differential counts, and platelet counts remained unaffected by the vanadium treatments.
- Osmotic fragility of erythrocytes showed no significant alterations, indicating no impact on red blood cell integrity.
Conclusions:
- Oral administration of ammonium metavanadate, vanadyl sulphate, and bis(maltolato)oxovanadium (i.v.) did not result in significant haematological toxicity in Wistar rats.
- The tested vanadium compounds appear safe concerning haematological parameters at the studied doses and exposure duration.
- These findings contribute to the understanding of vanadium compound safety in toxicological assessments.